Speaker illustration

Doctor Shinobu Sugihara

Mayo Clinic, Rochester (United States of America)

Subcutaneous delivery of NPA7, first-in-class novel bispecific designer peptide: enhances cardiorenal function and suppresses renin and aldosterone in vivo and in vitro

Event: ESC CONGRESS 2019

Topic: Pharmacotherapy

Session: Heart Failure Basic Science

Thumbnail

This platform is supported by

logo Novo Nordisk